Some researchers suggested that CD4+ T cells can predict clinical response to anti-PD-L1 (Oh et al., 2020) and are involved with better prognosis (Ahlen Bergman et al., 2018), but others found that CD4+ T cells can promote cancer metastasis in BLCA (Tao et al., 2018). This evidence concerns the gene CD4 and bladder transitional cell carcinoma.